Accelerated Approval May Support Smaller Trials In Acute Diseases – FDA
Executive Summary
Final guidance on expedited regulatory pathways suggests FDA is open to accelerated approval for some acute conditions; agency also provides examples outside of HIV/cancer arena where surrogate and intermediate clinical endpoints have supported approval.
You may also be interested in...
Accelerated Approval Should Be Less 'Wide Open,' Califf Says
FDA should write more about its interpretation of regs and apply it more consistently across divisions, commissioner says.
FDA Accelerated Approval For Rare Diseases Again Under Congressional Pressure
Letter being circulated by Rep. Bilirakis states the agency’s draft expedited approval guidance does not provide clarity for rare disease sponsors to use accelerated approval.
Accelerated Approval: Potential Sources Of Confirmatory Evidence Weighed At Tofersen Review
‘Clear signal’ in the ATLAS study of presymptomatic, SOD1 mutation carriers could provide evidence needed to confirm tofersen’s benefit in symptomatic ALS patients, FDA’s Teresa Buracchio says, adding that getting confirmatory evidence from the VALOR open-label extension 'could be a little more tricky.'